British Columbia

Aptiom^® (eslicarbazepine acetate) - Special Authorization

For the treatment of partial-onset seizures in adults and to be used:

• As adjunctive therapy (used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures AND
• After at least FOUR other anti-epileptic medications have been tried without success (names of previously tried therapies and response to those therapies must be documented on the Special Authority Request).

Examples of other anti-epileptic drugs include: phenytoin, carbamazepine, gabapentin, topiramate, lamotrigine, levetiracetam, lacosamide, perampanel, vigabatrin, and valproic acid.

Alberta

Aptiom^® (eslicarbazepine acetate) - Special Authorization

For adjunctive therapy in patients with refractory partial-onset seizures who meet all of the following criteria:

• Are currently receiving two or more antiepileptic medications, AND
• Have failed or demonstrated intolerance to three other antiepileptic medications, AND
• Therapy must be initiated by a neurologist.

Saskatchewan

Aptiom^® (eslicarbazepine acetate) - Exception Drug Status

For the adjunctive treatment of refractory partial-onset seizures in patients who meet all of the following:

• Are currently receiving two or more antiepileptic drugs; AND
• Less costly antiepileptic drugs are ineffective or inappropriate; AND
• The medication is being used under the direction of a neurologist.

Manitoba

Aptiom^® (eslicarbazepine acetate) - Exception Drug Status

For use as an adjunctive therapy in patients in the management of refractory partial-onset seizures (POS) in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy and who meet all of the following criteria:

• Are under the care of a physician experienced in the treatment of epilepsy,
• Are currently receiving two or more antiepileptic drugs, and
• In whom all other antiepileptic drugs are ineffective or not appropriate.

Ontario

Aptiom^® (eslicarbazepine acetate) - Limited Use (Code 430)

As adjunctive therapy in the treatment of adult patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies;
AND
Patients are under the care of a physician experienced in the treatment of epilepsy.

Note: Less costly anticonvulsant therapies may include the following: phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc.

Newfoundland and Labrador

Aptiom^® (eslicarbazepine acetate) - Special Authorization

For the treatment of patients with refractory partial-onset seizures as adjunctive therapy who meet all of the following criteria:

• Are under the care of a neurologist or physician experienced in the treatment of epilepsy AND
• Are currently receiving two or more antiepileptic drugs AND
• In whom all other antiepileptic drugs are ineffective or not appropriate.

Yukon Territory

Aptiom^® (eslicarbazepine acetate) – Exception Drug Status

For patients with refractory partial-onset seizures who are under the care of a physician experienced in the treatment of epilepsy, and are currently receiving two or more antiepileptic agents, and in whom all other antiepileptic medications are ineffective or not appropriate.

Quebec

Aptiom^® (eslicarbazepine acetate) – Médicament d’exception*

Code de medicaments d’exception: SN156

Pour le traitement d’appoint des personnes atteintes d’épilepsie focale réfractaire, c’est-à-dire à la suite de l’échec de deux medicaments anticrises appropriés et tolérés (utilisés soit en monothérapie ou en combinaison).
Note : L'intolérance ou la contre-indication à deux médicaments anticrises ne satisfait pas à l'indication de paiement.
*https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/codes-medicaments-exception/codes_medicaments_exception.pdf.

Exceptional medication code: SN156

For adjunctive treatment of persons suffering from refractory focal epilepsy, that is, following the failure of two appropriate and tolerated anti-seizure drugs (used only in either as monotherapy or in combination).
Note: Intolerance or contraindication to two antiseizure medications will not satisfy the indication of payment.
*https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/codes-medicaments-exception/codes_medicaments_exception.pdf.

Marque officielle de la Régie de l’assurance maladie du Québec. Liste des médicaments de la RAMQ : https://www.ramq.gouv.qc.ca/sites/default/files/documents/non_indexes/liste_med_2023-12-13_fr.pdf. Official Mark of the Régie de l’assurance maladie du Québec. RAMQ List of Médications: https://www.ramq.gouv.qc.ca/sites/default/files/documents/non_indexes/liste_med_2023-12-13_en.pdf.

New Brunswick

Aptiom^® (eslicarbazepine acetate) – Special Authorization

For the adjunctive treatment of refractory partial-onset seizures in patients:

• Who are currently receiving two or more antiepileptic drugs, AND
• Who have had an inadequate response or intolerance to at least three other antiepileptic drugs.

• The patient must be under the care of a physician experienced in the treatment of epilepsy.

Prince Edward Island

Aptiom^® (eslicarbazepine acetate) – Special Authorization

For the treatment of partial-onset seizures in patients with epilepsy who are currently receiving two or more antiepileptic drugs (AEDs) and for whom less costly AEDs are ineffective or not clinically appropriate.

Nova Scotia

Aptiom^® (eslicarbazepine acetate) – Exception Status

As adjunctive treatment for patients with refractory partial-onset seizures who meet all of the following criteria:

• Are under the care of a physician experienced in the treatment of epilepsy, AND
• Are currently receiving two or more antiepileptic drugs, AND
• In whom all other antiepileptic drugs are ineective or not appropriate

• Any combination of lacosamide, perampanel or eslicarbazepine will not be reimbursed.

NWT/Nunavut NIHB*

Limited Use Benefit

For adjunctive therapy in patients with refractory partial-onset seizures who meet all of the following criteria:

• Are under the care of a physician experienced in the treatment of epilepsy, and AND
• Are currently receiving two or more antiepileptic medications, and AND
• Have failed or demonstrated intolerance to at least two other antiepileptic medications.